Showing results (1501-1510 of 1,887) with videos related to

Sort By:
Pageof 189
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2020
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE studyM Augustin, C E Kleyn, C Conrad, et al.
Scientific Reports|December 22, 2015
Patients' experience of Chinese Medicine Primary Care Services: Implications on Improving Coordination and Continuity of CareVincent Ch Chung, Benjamin Hk Yip, Sian M Griffiths, et al.
The British Journal of Dermatology|November 25, 2014
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialR Bissonnette, L Iversen, H Sofen, et al.
Plos One|December 17, 2011
Actin nemaline myopathy mouse reproduces disease, suggests other actin disease phenotypes and provides cautionary note on muscle transgene expressionGianina Ravenscroft, Connie Jackaman, Caroline A Sewry, et al.
The New England Journal of Medicine|May 12, 2021
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaAndrew Menzies-Gow, Jonathan Corren, Arnaud Bourdin, et al.
Chemico-Biological Interactions|January 24, 2006
In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavengerD M Cerasoli, E M Griffiths, B P Doctor, et al.
Contact Dermatitis|March 5, 2025
The Prevalence and Severity of Hand Eczema Among Adults in Tasiilaq, East GreenlandMorten Bahrt Haulrig, Anna M Andersson, Julia-Tatjana Maul, et al.
Gastro Hep Advances|August 12, 2024
A Machine Learning Approach to Identifying Causal Monogenic Variants in Inflammatory Bowel DiseaseDaniel J Mulder, Sam Khalouei, Michael Li, et al.
JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.
The British Journal of Dermatology|October 10, 2017
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)K A Papp, C L Leonardi, A Blauvelt, et al.
Pageof 189